Amdocs (DOX) Lands VEON Deal, Is The Stock Still Undervalued?
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Amdocs (DOX) recently secured a 10-year technology agreement with VEON, which involves modernizing VEON's operations and integrating QazCode's AI capabilities into Amdocs' aOS telecom platform. Despite a recent stock rebound, Amdocs' year-to-date performance remains down, though many analysts consider it undervalued with a fair value of $82.03 against a current price of approximately $60.25. The company exhibits strong recurring revenue streams and a disciplined capital allocation strategy, but faces risks if telecom spending slows or GenAI investments do not yield profitable contracts.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.